Sandu [SANDUPHQ] vs Suven Life Sciences [SUVEN] Detailed Stock Comparison
Sandu
BSE
Loading...
Suven Life Sciences
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Sandu wins in 10 metrics, Suven Life Sciences wins in 8 metrics, with 0 ties. Sandu appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Sandu | Suven Life Sciences | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 27.81 | -28.01 | Suven Life Sciences |
| Price-to-Book Ratio | 1.05 | 40.49 | Sandu |
| Debt-to-Equity Ratio | 1.14 | 0.00 | Suven Life Sciences |
| PEG Ratio | 0.79 | -0.34 | Suven Life Sciences |
| EV/EBITDA | 14.56 | -23.32 | Suven Life Sciences |
| Profit Margin (TTM) | 2.41% | 84.44% | Suven Life Sciences |
| Operating Margin (TTM) | 2.08% | -2,791.92% | Sandu |
| EBITDA Margin (TTM) | 2.08% | N/A | N/A |
| Return on Equity | 3.69% | -146.15% | Sandu |
| Return on Assets (TTM) | 2.78% | -118.91% | Sandu |
| Free Cash Flow (TTM) | $104,000 | $-1.91B | Sandu |
| Dividend Yield | 1.61% | N/A | N/A |
| 1-Year Return | -22.09% | 46.77% | Suven Life Sciences |
| Price-to-Sales Ratio (TTM) | 0.67 | 641.26 | Sandu |
| Enterprise Value | $426.40M | $43.40B | Suven Life Sciences |
| EV/Revenue Ratio | 0.64 | 577.38 | Sandu |
| Gross Profit Margin (TTM) | 47.10% | 100.00% | Suven Life Sciences |
| Revenue per Share (TTM) | $69 | $0 | Sandu |
| Earnings per Share (Diluted) | $1.66 | $-8.15 | Sandu |
| Beta (Stock Volatility) | 0.17 | 0.86 | Sandu |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Sandu vs Suven Life Sciences Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Sandu | 0.26% | -0.13% | -3.60% | -7.75% | -4.91% | -17.81% |
| Suven Life Sciences | 0.80% | -0.17% | -3.10% | -15.83% | 58.82% | 63.15% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Sandu | -22.09% | -33.31% | 42.40% | 36.12% | 219.17% | 98.20% |
| Suven Life Sciences | 46.77% | 186.97% | 307.88% | -25.87% | 594.28% | 3,728.07% |
News Based Sentiment: Sandu vs Suven Life Sciences
Sandu
News based Sentiment: NEGATIVE
September was a significantly negative month for Sandu Pharmaceuticals, characterized by a consistent decline in stock price, a shift in valuation to 'fair', and the first revenue contraction in three years. These developments, coupled with a notable stake sale and declining investor participation, create a concerning picture for investors and suggest a challenging period ahead for the company.
Suven Life Sciences
News based Sentiment: POSITIVE
The month of October 2025 saw Suven Life Sciences benefit from both company-specific gains and a broader pharmaceutical rally, indicating a positive trend for the company. The Pfizer agreement acted as a catalyst for this positive movement, suggesting a favorable market environment.
Performance & Financial Health Analysis: Sandu vs Suven Life Sciences
| Metric | SANDUPHQ | SUVEN |
|---|---|---|
| Market Information | ||
| Market Cap | ₹461.45M | ₹48.20B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 1,224 | 185,019 |
| 90 Day Avg. Volume | 1,326 | 147,095 |
| Last Close | ₹46.28 | ₹208.70 |
| 52 Week Range | ₹43.75 - ₹62.80 | ₹102.50 - ₹299.99 |
| % from 52W High | -26.31% | -30.43% |
| All-Time High | ₹86.00 (Apr 25, 2022) | ₹338.50 (Apr 13, 2015) |
| % from All-Time High | -46.19% | -38.35% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.02% | 0.86% |
| Quarterly Earnings Growth | 0.34% | 0.86% |
| Financial Health | ||
| Profit Margin (TTM) | 0.02% | 0.84% |
| Operating Margin (TTM) | 0.02% | -27.92% |
| Return on Equity (TTM) | 0.04% | -1.46% |
| Debt to Equity (MRQ) | 1.14 | 0.00 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹43.77 | ₹5.04 |
| Cash per Share (MRQ) | ₹2.73 | ₹2.75 |
| Operating Cash Flow (TTM) | ₹5.35M | ₹-1,590,282,000 |
| Levered Free Cash Flow (TTM) | ₹15.52M | ₹-1,607,450,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | 1.61% | N/A |
| Last 12-Month Dividend | ₹0.80 | ₹0.00 |
Valuation & Enterprise Metrics Analysis: Sandu vs Suven Life Sciences
| Metric | SANDUPHQ | SUVEN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 27.81 | -28.01 |
| Forward P/E | N/A | 10.55 |
| PEG Ratio | 0.79 | -0.34 |
| Price to Sales (TTM) | 0.67 | 641.26 |
| Price to Book (MRQ) | 1.05 | 40.49 |
| Market Capitalization | ||
| Market Capitalization | ₹461.45M | ₹48.20B |
| Enterprise Value | ₹426.40M | ₹43.40B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.64 | 577.38 |
| Enterprise to EBITDA | 14.56 | -23.32 |
| Risk & Other Metrics | ||
| Beta | 0.17 | 0.86 |
| Book Value per Share (MRQ) | ₹43.77 | ₹5.04 |
Financial Statements Comparison: Sandu vs Suven Life Sciences
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SANDUPHQ | SUVEN |
|---|---|---|
| Revenue/Sales | ₹166.99M | ₹18.67M |
| Cost of Goods Sold | ₹88.33M | ₹0 |
| Gross Profit | ₹78.66M | ₹18.67M |
| Research & Development | N/A | ₹414.88M |
| Operating Income (EBIT) | ₹3.48M | ₹-521.17M |
| EBITDA | ₹5.43M | ₹-501.49M |
| Pre-Tax Income | ₹3.39M | ₹-515.17M |
| Income Tax | ₹1.15M | ₹0 |
| Net Income (Profit) | ₹2.23M | ₹-515.17M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SANDUPHQ | SUVEN |
|---|---|---|
| Cash & Equivalents | ₹13.04M | ₹150.26M |
| Total Current Assets | ₹262.99M | ₹754.72M |
| Total Current Liabilities | ₹120.86M | ₹234.86M |
| Long-Term Debt | ₹4.19M | N/A |
| Total Shareholders Equity | ₹420.17M | ₹1.10B |
| Retained Earnings | ₹95.24M | ₹-6.01B |
| Property, Plant & Equipment | ₹7.46M | ₹756.69M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SANDUPHQ | SUVEN |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SANDUPHQ | SUVEN |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 1,224 | 185,019 |
| Average Daily Volume (90 Day) | 1,326 | 147,095 |
| Shares Outstanding | 9.66M | 218.07M |
| Float Shares | 3.24M | 67.61M |
| % Held by Insiders | 0.66% | 0.69% |
| % Held by Institutions | 0.00% | 0.02% |
Dividend Analysis & Yield Comparison: Sandu vs Suven Life Sciences
| Metric | SANDUPHQ | SUVEN |
|---|---|---|
| Last 12-Month Dividend | ₹0.80 | ₹0.00 |
| Last 12-Month Dividend Yield | 1.61% | N/A |
| 3-Year Avg Annual Dividend | ₹1.02 | ₹0.00 |
| 3-Year Avg Dividend Yield | 1.12% | N/A |
| 3-Year Total Dividends | ₹3.05 | ₹0.00 |
| Ex-Dividend Date | Sep 19, 2024 | N/A |